Kevin Outterson, JD, LLM
Professor of Law and N. Neal Pike Scholar
Boston University School of Law
Dept of Health and Disability Law

LLM, University of Cambridge
JD, Northwestern University School of Law

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Associate Professor of Health Law, Ethics & Human Rights
Boston University School of Public Health
Health Law, Policy & Management
Center for Health Law, Ethics & Human Rights

Executive Director of CARB-X
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

04/01/2019 - 03/31/2023 (Multi-PI)
PI: Kevin Outterson, JD, LLM
University of Antwerp European Commission

Accelerating the Development of innovative Preventive Approaches to Combat AMR
01/01/2019 - 12/31/2022 (PI)
The German Federal Ministry of Education and Research

RESTRICTED: Accelerating the Development of Innovative Preventive Approaches to Combat AMR
01/01/2019 - 12/31/2022 (PI)
The German Federal Ministry of Education and Research

WT CARB-X Core Mgmt/Other Program Support
01/01/2019 - 07/31/2022 (PI)
Wellcome Trust

WT CARB-X PD/Acc Costs Cost-Share
04/01/2017 - 07/31/2022 (PI)
Wellcome Trust

WT CARB-X Non Awardee Costs
04/01/2017 - 07/31/2022 (PI)
Wellcome Trust

08/01/2016 - 07/31/2022 (PI)
HHS/Assistant Secretary for Preparedness and Response
6 IDSEP160030-05-04

Accelerating the Development ofinnovative Preventive Approaches to Combat AMR
05/18/2018 - 05/31/2022 (PI)
Bill and Melinda Gates Foundation

05/18/2018 - 03/31/2022 (PI)
Department of Health and Social Care


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Nanayakkara AK, Boucher HW, Fowler VG, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. CA Cancer J Clin. 2021 Sep 21. PMID: 34546590
  2. Outterson K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020. Clin Infect Dis. 2021 Jul 12. PMID: 34251436
  3. Kållberg C, Hudson J, Salvesen Blix H, Årdal C, Klein E, Lindbæk M, Outterson K, Røttingen JA, Laxminarayan R. The effect of generic market entry on antibiotic prescriptions in the United States. Nat Commun. 2021 05 18; 12(1):2937. PMID: 34006862; PMCID: PMC8131704; DOI: 10.1038/s41467-021-23049-4;
  4. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. Clin Infect Dis. 2021 05 04; 72(9):e420-e421. PMID: 31999818
  5. Puzniak L, Gupta V, Yu KC, Ye G, Outterson K. The impact of infections on reimbursement in 92 US hospitals, 2015-2018. Am J Infect Control. 2021 10; 49(10):1275-1280. PMID: 33891989
  6. Kim W, Krause K, Zimmerman Z, Outterson K. Improving data sharing to increase the efficiency of antibiotic R&D. Nat Rev Drug Discov. 2021 01; 20(1):1-2. PMID: 33097914
  7. Minssen T, Outterson K, Rogers Van Katwyk S, Batista PHD, Chandler CIR, Ciabuschi F, Harbarth S, Kesselheim AS, Laxminarayan R, Liddell K, Osterholm MT, Price L, Hoffman SJ. Social, cultural and economic aspects of antimicrobial resistance. Bull World Health Organ. 2020 Dec 01; 98(12):823-823A. PMID: 33293739; PMCID: PMC7716096; DOI: 10.2471/BLT.20.275875;
  8. Morel CM, Alm RA, Årdal C, Bandera A, Bruno GM, Carrara E, Colombo GL, de Kraker MEA, Essack S, Frost I, Gonzalez-Zorn B, Goossens H, Guardabassi L, Harbarth S, Jørgensen PS, Kanj SS, Kostyanev T, Laxminarayan R, Leonard F, Hara GL, Mendelson M, Mikulska M, Mutters NT, Outterson K, Bano JR, Tacconelli E, Scudeller L. A one health framework to estimate the cost of antimicrobial resistance. Antimicrob Resist Infect Control. 2020 11 26; 9(1):187. PMID: 33243302; PMCID: PMC7689633; DOI: 10.1186/s13756-020-00822-6;
  9. Kirchhelle C, Atkinson P, Broom A, Chuengsatiansup K, Ferreira JP, Fortané N, Frost I, Gradmann C, Hinchliffe S, Hoffman SJ, Lezaun J, Nayiga S, Outterson K, Podolsky SH, Raymond S, Roberts AP, Singer AC, So AD, Sringernyuang L, Tayler E, Rogers Van Katwyk S, Chandler CIR. Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy. BMJ Glob Health. 2020 09; 5(9). PMID: 32967980; PMCID: PMC7513567; DOI: 10.1136/bmjgh-2020-003091;
  10. Rex JH, Outterson K. Antibacterial R&D at a crossroads: We've pushed as hard as we can … now we need to start pulling! Clin Infect Dis. 2020 Jun 25. PMID: 32584949
Showing 10 of 83 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 83 publications over 20 distinct years, with a maximum of 9 publications in 2011

Contact for Mentoring:

765 Commonwealth Ave
Boston MA 02215
Google Map

Outterson's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People